Oct 21, 2019
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting
Sep 27, 2019
Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission
Sep 17, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer
Jul 29, 2019
Mylan Reports Second Quarter 2019 Results
Jul 08, 2019
Mylan and Atomo Diagnostics Announce WHO Prequalification Approval for Mylan HIV Self Test
Jun 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
May 20, 2019
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
May 18, 2019
Mylan Presents Equivalence and Device Usability Data on Wixela(TM) Inhub(TM) Compared to Advair Diskus® at American Thoracic Society International Conference
May 10, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets
May 10, 2019
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
Apr 26, 2019
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019
Apr 18, 2019
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB)
Apr 03, 2019
Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available
Mar 18, 2019
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter
Mar 07, 2019
SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation
Feb 22, 2019
Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence
Feb 12, 2019
Mylan Launches Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand
Feb 11, 2019
Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019
Jan 31, 2019
Mylan Announces FDA Approval of Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
Dec 20, 2018
Mylan to Present at the 37th Annual J.P. Morgan Healthcare Conference